Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Stellar (XLM) Price Analysis: Can XLM Reach $0.30 After Breaking $0.22 Resistance?

Stellar (XLM) Price Analysis: Can XLM Reach $0.30 After Breaking $0.22 Resistance?

CryptoNewsNetCryptoNewsNet2026/10/03 23:15
Back to the list

Stellar (XLM) Price Analysis: Can XLM Reach $0.30 After Breaking $0.22 Resistance?

28 m

Stellar ($XLM) has pulled back after a strong September rally where it gained nearly 26% before the momentum weakened near $0.23 to $0.24. It is currently trading at $0.22, raising speculation about whether this consolidation can support another move higher. The weekly chart shows $XLM forming a long-term symmetrical triangle, while the derivatives are also rising. Therefore, a breakout above $0.25 could put $0.30 in focus, but the $XLM price is required to clear resistance and sustain buying pressure.

The $XLM price is trading within a large symmetrical triangle on the weekly chart. The upper trendline has capped several rallies since the 2025 peak. The lower trendline has provided support during the recent recovery, and these two lines are now moving close to each other. Currently, the price is testing the $0.22 to $0.24 resistance zone, which combines horizontal resistance with the descending trend line. Hence, a weekly close above the range could strengthen the bullish setup.

The volume profile shows significant trading activity around the current price range, making the $0.20 to $0.22 region important for the next price action. Volume has increased during recent price recoveries, where a stronger volume expansion would add confirmation to any breakout. Besides, the open interest has climbed toward $209 million, and the rise shows increasing participation in $XLM futures as price approaches resistance.

The $XLM price is approaching a key decisive zone near $0.22 after months of consolidation inside a symmetrical triangle. A weekly breakout above this range could put $0.27 in focus first, followed by $0.30 as the main upside target. If the momentum strengthens further, $0.35 could become the next resistance area. However, failure to clear the current range could send the Stellar price toward $0.20 to $0.16. For October, the $0.25 breakout zone remains the key level that could determine $XLM’s next move.

News Image 0News Image 1News Image 2
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

路透社•2026/10/09 04:26
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low

UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.

智通财经•2026/10/09 03:53